Market Research Logo

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Pipeline Review, H2 2016

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Pipeline Review, H2 2016’, provides in depth analysis on Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted pipeline therapeutics.

The report provides comprehensive information on the Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.
  • Updated report will be delivered in 48 hours of order confirmation.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape for Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119)
    • The report reviews Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved in Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics and enlists all their major and minor projects
    • The report assesses Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news and deals related to Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand the targeted therapy areas and indications for Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119)
    • Identify the use of drugs for target identification and drug repurposing
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) development landscape
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) Overview
Therapeutics Development
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Products under Development by Stage of Development
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Products under Development by Therapy Area
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Products under Development by Indication
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Products under Development by Companies
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Companies Involved in Therapeutics Development
Amgen Inc.
Array BioPharma Inc.
Astellas Pharma Inc.
CymaBay Therapeutics, Inc.
Daiichi Sankyo Company, Limited
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
Hyundai Pharmaceutical Co., Ltd.
LG Life Science LTD.
Merck & Co., Inc.
Novartis AG
Sanwa Kagaku Kenkyusho Co., Ltd.
Taisho Pharmaceutical Holdings Co., Ltd.
Takeda Pharmaceutical Company Limited
Yuhan Corporation
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Drug Profiles
17-i - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARRY-981 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AS-1669058 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DA-1241 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DS-8500 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2041706 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HD-0471042 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HD-0471953 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HOB-047 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LC-34AD3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MBX-2982 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize GPR119 for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize GPR119 for Type II Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize GPR119 for Undisclosed Indication - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize GPR119 Receptor for Undisclosed Indication - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize GPR119 for Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize GPR119 for Type II Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize GPR119 Receptor for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize GPR119 Receptor for Type II Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YH-18420 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Dormant Projects
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Discontinued Products
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Featured News & Press Releases
Nov 05, 2009: Metabolex Closes $8.6 Million Financing Round
Nov 12, 2008: Metabolex Announces Positive Results From Phase 1a Clinical Trial Of MBX-2982
Mar 26, 2008: Metabolex, Inc. Initiates Phase 1 Trial Of MBX-2982
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Number of Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Pipeline by Amgen Inc., H2 2016
Pipeline by Array BioPharma Inc., H2 2016
Pipeline by Astellas Pharma Inc., H2 2016
Pipeline by CymaBay Therapeutics, Inc., H2 2016
Pipeline by Daiichi Sankyo Company, Limited, H2 2016
Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
Pipeline by GlaxoSmithKline Plc, H2 2016
Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016
Pipeline by LG Life Science LTD., H2 2016
Pipeline by Merck & Co., Inc., H2 2016
Pipeline by Novartis AG, H2 2016
Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H2 2016
Pipeline by Taisho Pharmaceutical Holdings Co., Ltd., H2 2016
Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
Pipeline by Yuhan Corporation, H2 2016
Dormant Projects, H2 2016
Dormant Projects (Contd..1), H2 2016
Discontinued Products, H2 2016
List of Figures
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Indication, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report